Highlights of This Issue 5603

SPECIAL FEATURES

CCR Translations

5605  Heading in a New Direction: Drug Permeability in Breast Cancer Brain Metastasis
George W. Sledge, Jr.
See article p. 5664

CCR New Strategies

5608  New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies
Kieron Dunleavy, Richard L. Piekarz, Jasmine Zain, John E. Janik, Wyndham H. Wilson, Owen A. O’Connor, and Susan E. Bates

Molecular Pathways

5618  The Molecular Basis of Lmo2-Induced T-Cell Acute Lymphoblastic Leukemia
David J. Curtis and Matthew P. McCormack

5624  Targeting Hypoxic Cells through the DNA Damage Response
Monica Olcina, Philip S. Lecane, and Ester M. Hammond

CANCER THERAPY: PRECLINICAL

5664  Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman, Rajendar K. Mittapalli, Kunal S. Taskar, Vinay Rudraraju, Brunilde Gril, Kaci A. Bohn, Chris E. Adkins, Amanda Roberts, Helen R. Thorsheim, Julie A. Caasch, Suyun Huang, Diane Palmieri, Patricia S. Steeg, and Quentin R. Smith
See commentary p. 5605

5679  Quercetin Induces Tumor-Selective Apoptosis through Downregulation of Mcl-1 and Activation of Bax
Senping Cheng, Ning Gao, Zhou Zhang, Gang Chen, Amit Budhraja, Zunjie Ke, Young-ok Son, Xin Wang, Jia Luo, and Xianglin Shi

HUMAN CANCER BIOLOGY

5630  Benign Mesenchymal Stromal Cells in Human Sarcomas

5641  Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion
Laura Mosca, Sonia Fabris, Marta Lionetti, Katia Todoerti, Luca Agnelli, Fortunato Morabito, Giovanna Cutrara, Adrian Andronache, Serena Mattis, Francesco Ferrari, Massimo Gentile, Mauro Spriano, Vincenzo Callea, Gianluca Festini, Stefano Molica, Giorgio Lambertenghi Dellieres, Silvio Bicciato, Manlio Ferrari, and Antonino Neri

5654  Foxo3a Suppression of Urothelial Cancer Invasiveness through Twist1, Y-Box–Binding Protein 1, and E-Cadherin Regulation
Masaki Shiota, YooHyun Song, Akira Yokomizo, Keijiro Kiyoshima, Yasuhiro Tada, Hiroshi Uchino, Takeshi Uchiumi, Junichi Inokuchi, Yoshinao Oda, Kentaro Kurowia, Katsunori Tatsugami, and Seiji Naito
Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma

Highly Purified Eicosapentaenoic Acid as Free Fatty Acids Strongly Suppresses Polyps in ApcMin/+ Mice
Lucia Fini, Giulia Piazzia, Claudio Ceccarelli, Yahya Daoud, Andrea Belluzzi, Alessandra Munarini, Giulia Graziani, Vincenzo Fogliano, Michael Selgrad, Melissa Garcia, Antonio Gasbarrini, Robert M. Gent, C. Richard Boland, and Luigi Ricciardiello

Noninvasive Radiofrequency Field Destruction of Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles
Evan S. Glazer, Cihui Zhu, Kathryn L. Massey, C. Shea Thompson, Warna D. Kaluarachchi, Amir N. Hamir, and Steven A. Curley

Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses
Ling-Yuan Kong, Adam S. Wu, Tiffany Doucette, Jun Wei, Waldemar Priebe, Gregory N. Fuller, Wei Qiao, Raymond Sawaya, Ganesh Rao, and Amy B. Heimberger

TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors
Dominic Stadel, Andrea Mohr, Caroline Ref, Marion MacFarlane, Shaoxia Zhou, Robin Humphreys, Max Bachem, Gerry Cohen, Peter Möller, Ralf M. Zwacka, Klaus-Michael Debatin, and Simone Fulda

Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts
Wei-meng Zhao, Lihong Wang, Hangil Park, Sophie Chhim, Melanie Tanphanich, Masakazu Yashiro, and K. Jin Kim

Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer
Yuqi Guo, Jeffrey Nemeth, Colin O’Brien, Michiro Susa, Xianzhe Liu, Zhan Zhang, Edwin Choy, Henry Mankin, Francis Hornick, and Zhenfeng Duan

CEBPΔ Reverses RB/E2F1-Mediated Gene Repression and Participates in HMDB-Induced Apoptosis of Cancer Cells
Yen-Chun Pan, Chien-Feng Li, Chiung-Yuan Ko, Min-Hsiung Pan, Pei-Jung Chen, Joseph T. Tseng, Wen-Chun Wu, Wen-Chang Chang, A-Mei Huang, Esta Sterneck, and Ju-Ming Wang

Dietary Curcumin Attenuates Glioma Growth in a Syngeneic Mouse Model by Inhibition of the JAK1,2/STAT3 Signaling Pathway
Jakob Weissenberger, Maike Priester, Christian Berneuther, Stefanie Rake, Markus Glatzel, Volker Seifert, and Donat Kögel

DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer
Brian M. Alexander, Kam Sprott, D. Allan Farrow, XiaoZhe Wang, Alan D. D’Andrea, Stuart J. Schnitt, Laura C. Collins, David T. Weaver, and Judy E. Garber

High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
Steven C.H. Kao, Nick Pavlakis, Rozelle Harvie, Janette L. Vardy, Michael J. Boyer, Nico van Zandwijk, and Stephen J. Clarke

Expression of Snail in Upper Urinary Tract Urothelial Carcinoma: Prognostic Significance and Implications for Tumor Invasion
Takeo Kosaka, Eiji Kikuchi, Shuji Mikami, Akira Miyajima, Suguru Shirotake, Masaru Ishida, Yasunori Okada, and Mototsugu Oya
Inflammatory and MicroRNA Gene Expression as Prognostic Classifier of Barrett’s Associated Esophageal Adenocarcinoma
Giang Huong Nguyen, Aaron J. Schetter, David B. Chou, Elise D. Bowman, Ronghua Zhao, Jason E. Hawkes, Ewy A. Mathe, Kensuke Kumamoto, Yiqiang Zhao, Anuradha Budhu, Nobutoshi Hagiwara, Xin Wei Wang, Masao Miyashita, Alan G. Casson, and Curtis C. Harris

Urine Metabolite Analysis Offers Potential Early Diagnosis of Ovarian and Breast Cancers
Carolyn M. Slupsky, Helen Steed, Tiffany H. Wells, Kelly Dabbs, Alexandra Schepansky, Valerie Capstick, Wylam Faught, and Michael B. Sawyer

Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples
Vera L. Costa, Rui Henrique, Stine A. Danielsen, Sara Duarte Pereira, Mette Eknaes, Rolf I. Skotheim, Angelo Rodrigues, José S. Magalhães, Jorge Oliveira, Ragnhild A. Lothe, Manuel R. Teixeira, Carmen Jerónimo, and Guro E. Lind

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Stephanie Heon, Beow Y. Yeap, Gregory J. Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, and Bruce E. Johnson

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials

Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
Ahmad Tarhini, Athanasios Kotsakis, William Gooding, Yongli Shuai, Daniel Petro, David Friedland, Chandra P. Belani, Sanja Dacic, and Athanassios Arigiris

CORRECTION
Correction: Systems-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma

CANCER THERAPY: CLINICAL

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Stephanie Heon, Beow Y. Yeap, Gregory J. Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, and Bruce E. Johnson

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
Ahmad Tarhini, Athanasios Kotsakis, William Gooding, Yongli Shuai, Daniel Petro, David Friedland, Chandra P. Belani, Sanja Dacic, and Athanassios Arigiris

CORRECTION
Correction: Systems-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment

Correction: Systems-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma

CORRECTION
Correction: Systems-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma

The Journal of Clinical and Translational Research v www.aacrjournals.org
ABOUT THE COVER

Brain metastases of breast cancer are associated with significant morbidity and mortality. In their study, Lockman and colleagues quantified permeability, and paclitaxel and doxorubicin uptake in over 2000 experimental brain metastatic lesions from two model systems. The representative image shown on the cover is a multimodal image illustrating a single metastatic brain lesion which has 10 fold greater permeability compared to that of normal brain. Despite the increased permeability, drug accumulation only reached cytotoxic levels (>1000 ng/g) in a small subset of metastatic lesions, indicating that new brain-permeable drugs will be required. The picture was obtained by multichannel imaging of the eGFP MDA-MB-231Br lesion (green), indocyanine green within the vasculature (yellow), and 14C-AIB phosphorescence (red). For further details, please see Lockman and coworkers on page 5664 in this issue.